A Canary Islands Company Leads the Clinical Trial of a New Drug to Treat ALS
Following the discovery of several molecules by a CSIC research group, Molefy Pharma will become one of the first organizations worldwide to evaluate the viability of this new therapeutic approach. By Verónica Pavés. Santa Cruz de Tenerife. Originally published by El Día. A company based in the Canary Islands will lead the clinical trial of a promising new treatment aimed […]
Molefy Pharma launches new website to share breakthrough progress in ALS research and drug development
Santa Cruz de Tenerife, 9 de junio de 2025. Molefy Pharma, a biotech company born from the collaboration between ARQUIMEA and CSIC, has announced the launch of its new corporate website www.molefypharma.com , a platform designed to offer comprehensive insight into the company’s mission, scientific research, and advancements in the development of innovative treatments for […]